PMID- 18045968 OWN - NLM STAT- MEDLINE DCOM- 20080521 LR - 20211020 IS - 0006-4971 (Print) IS - 1528-0020 (Electronic) IS - 0006-4971 (Linking) VI - 111 IP - 4 DP - 2008 Feb 15 TI - Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. PG - 1999-2006 AB - A recombinant prodrug, single-chain urokinase-type plasminogen activator (scuPA) fused to an anti-PECAM-1 antibody single-chain variable fragment (anti-PECAM scFv/scuPA) targets endothelium and augments thrombolysis in the pulmonary vasculature.(1) To avoid premature activation and inactivation and to limit systemic toxicity, we replaced the native plasmin activation site in scFv/low-molecular-weight (lmw)-scuPA with a thrombin activation site, generating anti-PECAM scFv/uPA-T that (1) is latent and activated by thrombin instead of plasmin; (2) binds to PECAM-1; (3) does not consume plasma fibrinogen; (4) accumulates in mouse lungs after intravenous injection; and (5) resists PA inhibitor PAI-1 until activated by thrombin. In mouse models of pulmonary thrombosis caused by thromboplastin and ischemia-reperfusion (I/R), scFv/uPA-T provided more potent thromboprophylaxis and greater lung protection than plasmin-sensitive scFv/uPA. Endothelium-targeted thromboprophylaxis triggered by a prothrombotic enzyme illustrates a novel approach to time- and site-specific regulation of proteolytic reactions that can be modulated for therapeutic benefit. FAU - Ding, Bi-Sen AU - Ding BS AD - Department of Pharmacology, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA. FAU - Hong, Nankang AU - Hong N FAU - Murciano, Juan-Carlos AU - Murciano JC FAU - Ganguly, Kumkum AU - Ganguly K FAU - Gottstein, Claudia AU - Gottstein C FAU - Christofidou-Solomidou, Melpo AU - Christofidou-Solomidou M FAU - Albelda, Steven M AU - Albelda SM FAU - Fisher, Aron B AU - Fisher AB FAU - Cines, Douglas B AU - Cines DB FAU - Muzykantov, Vladimir R AU - Muzykantov VR LA - eng GR - HL076406/HL/NHLBI NIH HHS/United States GR - HL076206/HL/NHLBI NIH HHS/United States GR - R01 CA083121/CA/NCI NIH HHS/United States GR - P01 HL076406/HL/NHLBI NIH HHS/United States GR - R01 HL076206/HL/NHLBI NIH HHS/United States GR - CA83121/CA/NCI NIH HHS/United States GR - P01 HL079063/HL/NHLBI NIH HHS/United States GR - HL071174/HL/NHLBI NIH HHS/United States GR - HL079063/HL/NHLBI NIH HHS/United States GR - R01 HL071174/HL/NHLBI NIH HHS/United States GR - HL71175/HL/NHLBI NIH HHS/United States GR - R01 HL071175/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20071128 PL - United States TA - Blood JT - Blood JID - 7603509 RN - 0 (Platelet Endothelial Cell Adhesion Molecule-1) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Recombinant Proteins) RN - 9001-32-5 (Fibrinogen) RN - EC 3.4.21.5 (Thrombin) RN - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator) RN - U5NH2JV64T (saruplase) SB - IM MH - Animals MH - Endothelium, Vascular/drug effects/*physiology MH - Fibrinogen/metabolism MH - Humans MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Platelet Endothelial Cell Adhesion Molecule-1/metabolism/*physiology MH - Protein Binding MH - Pulmonary Circulation/*physiology MH - Recombinant Fusion Proteins/metabolism MH - Recombinant Proteins/metabolism/pharmacology MH - Thrombin/*physiology MH - *Thrombolytic Therapy MH - Tissue Distribution MH - Urokinase-Type Plasminogen Activator/genetics/metabolism/*physiology PMC - PMC2234048 EDAT- 2007/11/30 09:00 MHDA- 2008/05/22 09:00 PMCR- 2009/02/15 CRDT- 2007/11/30 09:00 PHST- 2007/11/30 09:00 [pubmed] PHST- 2008/05/22 09:00 [medline] PHST- 2007/11/30 09:00 [entrez] PHST- 2009/02/15 00:00 [pmc-release] AID - S0006-4971(20)44594-X [pii] AID - 2007/103002 [pii] AID - 10.1182/blood-2007-07-103002 [doi] PST - ppublish SO - Blood. 2008 Feb 15;111(4):1999-2006. doi: 10.1182/blood-2007-07-103002. Epub 2007 Nov 28.